Rasio utang jangka dawa marang modal cel-sci.com (CVM)

CEL-SCI Corp - logo grafis emiten CVM

CEL-SCI Corporation operates amid investor skepticism due to prolonged development timelines. The long-term financial leverage ratio demonstrates current stability, where the value of 0.45 reflects the current level of borrowings. Prospects depend on the certification of GMP facilities and the success of Multikine, as well as the flawless transportation of experimental vaccines between centers.

Utang jangka dawa marang modal: CEL-SCI Corp. (CVM) kanggo 04.07.2022 - 30.10.2026
Barang unggulan CEL-SCI Corporation

This ratio determines the share of long-term liabilities within the equity structure, measuring the company's degree of financial leverage. An increase in this metric signals a rising credit burden, which requires correlation with revenue growth rates. By analyzing the dynamics of long-term debt relative to equity, an investor can discern the actual trajectory of the debt policy. For CEL-SCI Corporation (CVM), low values confirm the efficiency of production outsourcing. The absence of significant capital expenditures minimizes the need for long-term borrowing.

Perusahaan pesaing

Utang jangka dawa marang modal BeiGene Ltd.|Utang jangka dawa marang ekuitas Halozyme Inc. (HALO)|Revolution Medicines Corp - Rasio utang jangka dawa marang modal|Utang jangka dawa marang modal AAPG (Ascentage Pharma Group)|CGON - Rasio utang jangka dawa marang ekuitas|UroGen Pharma - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Bicara Therapeutics Inc|Personalis Corp (PSNL) - Utang jangka dawa marang ekuitas|Erasca Oncology - Koefisien utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas DCTH|YMAB: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal AURA|Rasio utang jangka dawa marang ekuitas candeltx.com CADL|Accuray Inc. - Rasio utang jangka dawa marang ekuitas|Utang jangka dawa marang modal SELLAS Life Sciences Group, Inc. SLS|ACTU - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal CTOR (citiusonc.com)|HURA: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Protara Therapeutics Inc (TARA)|FATE (Fate Therapeutics Corp) - Utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas Aadi Bio (WHWK)|Utang jangka dawa marang modal TCRX|CSBR - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas XBiotech XBIT|OS Therapies Inc. - Utang jangka dawa marang ekuitas|RADX: Rasio utang jangka dawa marang ekuitas|Tanggungan utang jangka dawa marang ekuitas Artiva Biotherapeutics, Inc. (ARTV)|adlainortye.com (ANL) - Utang jangka dawa marang ekuitas|VERU - Rasio tanggungan utang jangka dawa marang modal|TPST (Tempest Therapeutics, Inc.) - Utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas Xilio (XLO)|Utang jangka dawa marang modal RENB|Rasio tanggungan utang jangka dawa marang modal muraloncology.com|Kairos Pharma - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal OKUR|CytoMed - Utang jangka dawa marang modal|Curis, Inc. (CRIS) - Rasio utang jangka dawa marang ekuitas|apollomicsinc.com (APLM) - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang modal Tharimmune Corporation (THAR)|Utang jangka dawa marang ekuitas Advanced Biomed Inc.|GNPX: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Calidi Biotherapeutics (CLDI)|SBFM: Kewajiban jangka dawa marang ekuitas|Utang jangka dawa marang ekuitas Xenetic Biosciences, Inc. XBIO|Salarius Pharma (SLRX) - Kewajiban jangka dawa marang modal|PPBT - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal AONC (American Oncology Network)|BGNE: Utang jangka dawa marang modal|Checkpoint Therapeutics Inc. (CKPT) - Utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas ELEV|ICAD (iCAD Corp) - Rasio silihan jangka dawa marang modal|Utang jangka dawa marang modal IKNA|Rasio tanggungan utang jangka dawa marang modal notablelabs.com|Utang jangka dawa marang ekuitas Viracta Therapeutics, Inc. VIRX|MorphoSys Inc (MOR) - Kewajiban jangka dawa marang modal|NAYA - Utang jangka dawa marang ekuitas|AAPGV (Ascentage) - Rasio utang jangka dawa marang modal